

Virtual Conference on

STAPHYLOCOCCAL INFECTIONS

Tuesday, May 10, 2022
Eastern Time (US & Canada)

SPONSOR





About Integrated BioTherapeutics



IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company's lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against *Staphylococcus aureus*. Supported by CARB-X and the Novo Holding's Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with clinical trials anticipated to begin in late 2022.

IBT and its subsidiary IBV (<http://www.integratedbiotherapeuticvaccines.com>) immunotherapeutic pipeline includes monoclonal antibodies for the treatment of the array of viruses that cause hemorrhagic fever. IBT also is developing product candidates for the treatment of *S. aureus*, anthrax, and *Clostridium difficile*, based on its proprietary Infection Site Targeted Antitoxin Antibody (ISTAb) technology.

Learn more about IBT's pipeline at <https://www.integratedbiotherapeutics.com/our-science/>.

IBT Bioservices, the contract research division of IBT, offers *in vitro* assays and animal infection models to enable lead-to-candidate selection and eventual progression to IND and clinical development.

To learn more visit <http://www.ibtbioservices.com> or email us at services@ibtbioservices.com.



Chair: **Nathan Archer**, Johns Hopkins School of Medicine, MD, USA

08:00-08:10 Welcome & Introduction to STAPH-2022

08:10-08:35 **Rhodomyrtone, an Interesting Plant-Derived Antibiotic**
Friedrich Götz, University of Tübingen, Germany

08:35-08:40 Q&A

08:40-09:05 ***Staphylococcus aureus* as Pathogen in Viral-Bacterial Co-Infections of the Lung**
Bettina Löffler, Jena University Hospital, Germany

09:05-09:10 Q&A

09:10-09:35 **What Makes Staphylococci So Sticky?**
Yves Dufrêne, UCLouvain, Belgium

09:35-09:40 Q&A

09:40-10:05 **Identifying Functional and Structural Epitopes in Staphylococcal Antigens by Phage Display**
Gregg J. Silverman, NYU Grossman School of Medicine, NY, USA

10:05-10:10 Q&A

10:10-10:20 Discussions

10:20-10:30 Break

10:30-10:55 **The Antibacterial Drone: A Novel Anti Staphylococcal Therapeutic Platform That Does Not Involve Antibiotics**
Richard P Novick, NYU Grossman School of Medicine, NY, USA

10:55-11:00 Q&A

11:00-11:25 **Phage Lysins: The Most Advanced Antibiotic Alternative to Control MRSA Infections**
Vincent A. Fischetti, Rockefeller University, NY, USA

11:25-11:30 Q&A

11:30-11:55 **Update on *Staphylococcus aureus* Vaccines**
Richard A Proctor, University of Wisconsin, WI, USA

11:55-12:00 Q&A

12:00-12:25 **Vaccination against Recurrent Skin and Soft Tissue Infection Caused by *Staphylococcus aureus***
M. Javad Aman, Integrated BioTherapeutics, MD, USA

12:25-12:30 Q&A

12:30-12:40 Discussions

12:40-12:50 Break

Chair: **George Sakoulas**, UCSD School of Medicine, CA, USA

12:50-13:15 **Staphylococcal Penicillin Binding Proteins (PBPs): New Approaches for an Old Target**
Jose Procopio Moreno Senna, FIOCRUZ, Brazil

13:15-13:20 Q&A

13:20-13:45 **Bacteria-Specific Phototoxicity to Multi-Drug Resistant Staph**
Mei X. Wu, Harvard Medical School, MA, USA

13:45-13:50 Q&A

13:50-14:15 **Using Anti-Virulence Inhibitor as an Alternative Strategy to Combat MRSA**
Yinduo Ji, University of Minnesota, MN, USA

14:15-14:20 Q&A

14:20-14:30 Discussions

14:30-14:40 Break

14:40-15:05 **Potentiating Antibiotic Efficacy Against Biofilm-Infected Wounds**
Sarah Rowe-Conlon, University of North Carolina, NC, USA

15:05-15:10 Q&A

15:10-15:35 **Engineered Human Antibodies for the Opsonization and Killing of *Staphylococcus aureus***
Dominique Missiakas, University of Chicago, IL, USA

15:35-15:40 Q&A

15:40-16:05 **The Impact of Iron Availability on the Small Colony Variant Phenotype of *Staphylococcus aureus***
Catherine A Wakeman, Texas Tech University, TX, USA

16:05-16:10 Q&A

16:10-16:20 Discussions

16:20-16:30 Concluding Remarks